Cerevel Therapeutics Holdings Inc

NASDAQ:CERE   3:59:53 PM EDT
33.50
+4.00 (+13.56%)
: $40.00 +6.50 (+19.40%)
Earnings Announcements

Cerevel Therapeutics Reports Second Quarter 2022 Financial Results

Published: 08/01/2022 12:02 GMT
Cerevel Therapeutics Holdings Inc (CERE) - Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates.
Cash, Cash Equivalents and Marketable Securities of $531m As of June 30, 2022, to Support Operations Into 2024.
Cerevel Therapeutics Holdings - Initiated Two Parallel, Adequately-powered Phase 2 Trials of Emraclidine in Schizophrenia With Data Expected 1h 2024.
Cerevel Therapeutics - Phase 1 Trial of Emraclidine to Be Initiated by Year-end to Support Future Development in Alzheimer's Disease Psychosis.
Qtrly Net Loss per Share, Basic and Diluted $0.61.
Q2 Earnings per Share View $-0.48 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.56

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.57

More details on our Analysts Page.